NCT04426825View on ClinicalTrials.gov

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 9, 2020

Primary Completion Date

January 19, 2022

Study Completion Date

February 10, 2023

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Atezolizumab

Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.

DRUG

Bevacizumab

Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

Trial Locations (10)

100142

Beijing Cancer Hospital, Beijing

100730

Beijing Hospital; Internal Medicine-Oncology, Beijing

101149

Beijing Chest Hospital; Oncology Department, Beijing

150081

Harbin Medical University Cancer Hospital, Harbin

250117

Shandong Cancer Hospital, Jinan

266000

The Affiliated Hospital of Medical College Qingdao University, Qingdao

310022

Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department, Hangzhou

510663

Sun Yet-sen University Cancer Center, Guangzhou

530021

Guangxi Cancer Hospital of Guangxi Medical University, Nanning

610041

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT04426825 - A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter